Evidence map›Paper›PMID 38841819›Full record

ArticleBrain and behavior2024

Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-Results from the MAGNON project.

Verena Isabell Leussink, Manda Jankovic, Marie Groth, Katrin Schuh, Inessa Schwab Sauerbeck, Olaf Hoffmann

Abstract read
In one paragraph

Article in Brain and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Verena Isabell LeussinkPraxis Neurologie in Meerbusch, Meerbusch, Germany.
Manda JankovicSauerlandklinik Hachen, Sundern, Germany.
Marie GrothClinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.
Katrin SchuhClinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.
Inessa Schwab SauerbeckClinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.
Olaf HoffmannSt. Josefs-Krankenhaus Potsdam-Sanssouci, Potsdam, Germany.ORCID 0000-0001-6399-1911

Funding

Novartis Pharma Vertriebs GmbH
6 · The paper itself

Abstract

backgroundThe revised Lublin classification offers a framework for categorizing multiple sclerosis (MS) according to the clinical course and imaging results. Diagnosis of secondary progressive MS (SPMS) is often delayed by a period of uncertainty. Several quantitative magnetic resonance imaging (qMRI) markers are associated with progressive disease states, but they are not usually available in clinical practice.

methodsThe MAGNON project enrolled 629 patients (early relapsing-remitting MS (RRMS), n = 51; RRMS with suspected SPMS, n = 386; SPMS, n = 192) at 55 centers in Germany. Routine magnetic resonance imaging (MRI) scans at baseline and after 12 months were analyzed using a centralized automatic processing pipeline to quantify lesions and normalized brain and thalamic volume. Clinical measures included relapse activity, disability, and MS phenotyping. Neurologists completed questionnaires before and after receiving the qMRI reports.

resultsAccording to the physicians' reports, qMRI results changed their assessment of the patient in 31.8% (baseline scan) and 27.6% (follow-up scan). For ∼50% of patients with RRMS with suspected SPMS, reports provided additional information that the patient was transitioning to SPMS. In >25% of all patients, this information influenced the physicians' assessment of the patient's current phenotype. However, actual changes of treatment were reported only in a minority of these patients.

conclusionsThe MAGNON results suggest that standardized qMRI reports may be integrated into the routine clinical care of MS patients and support the application of the Lublin classification as well as treatment decisions. The highest impact was reported in patients with suspected SPMS, indicating a potential to reduce diagnostic uncertainty.

Indexed as

BrainMagnetic Resonance ImagingMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingAdultDisease ProgressionFemaleGermanyHumansMaleMiddle AgedMultiple Sclerosisbrain volumemultiple sclerosis phenotypequantitative magnetic resonance imagingsecondary progressive multiple sclerosisthalamic volume

Identifiers

PMID38841819
PMCPMC11154816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.